Salvador Aguilar-Rosas

Salvador Aguilar-Rosas

Auto-generated profile, based on publicly available information

Salvador Aguilar-Rosas

CureVac Netherlands B.V., Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame peptides (NOP) expressed in tumors. We termed this collection of NOPs the tumor framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe a class of hidden NOPs that derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of noncoding regions of the genome downstream of a rearrangement breakpoint, i.e., where no gene annotation or evidence for transcription exists. The entire collection of NOPs represents a vast number of possible neoantigens particularly in tumors with many structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T cells specific for hidden NOPs in peripheral blood from a patient with lung cancer. This work highlights NOPs as a major source of possible neoantigens for personalized cancer immunotherapy and provides a rationale for analyzing the complete cancer genome and transcriptome as a basis for the detection of NOPs.

4 June 2024
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S14: A375 immunopeptidomics.

4 June 2024
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S12: Example of a genomic rearrangement resulting in the expression of multiple hidden NOPs in tumor sample BRE007.

4 June 2024
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S8: Comparison of EasyFuse short-read fusion gene caller with long-read and WGS guided NOP identification.

4 June 2024
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S11: Example of a hidden NOP resulting from a complex chromosomal rearrangement in tumor sample LUN022.

4 June 2024
Verified
Other
Open access
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Figure S16: Expansion of FRM-specific CD8T cells after priming with relevant peptide in PBMC from healthy individuals.